Secondary Malignant Neoplasm of Bone
Conditions
Keywords
Bone Metastasis, Pain Palliation, High Intensity Focused Ultrasound
Brief summary
Magnetic Resonance guided Focused Ultrasound (MRgFUS) has demonstrated to be effective for pain control through thermally-induced cell death and periosteal denervation caused by cortical heating relative to acoustic energy absorption. There is also evidence that a high intensity focused ultrasound beam can penetrate through the cortical bone to the medullary space, producing thermal necrosis of cancer tissue. However, little is known about the potential effects of MRgFUS as first line therapeutic modality for pain palliation in skeletal metastases. Our hypothesis sought to assess the clinical performance of MRgFUS primary treatment of painful bone metastases and determine the potential of this technique for local tumor control.
Detailed description
Unlike previous studies, in which patients were enrolled for MRgFUS treatment because of the failure of other therapies, our study will be conducted in patients not previously treated with EBRT to the targeted lesion. This is an important new feature, especially given the advantages of MRgFUS, such as lack of ionizing radiation, the ability to conduct treatment on an outpatient basis and the possibility to repeat the treatment as necessary.
Interventions
PROCEDUREMRgFUS
Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
Sponsors
University of Roma La Sapienza
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* the presence of a known primary cancer and bone metastases confirmed by two or more imaging modalities; * exhaustion or refusal of all other pain palliation methods including EBRT; * confirmation of MRgFUS treatment feasibility at a preliminary MR planning examination (presence of an adequate acoustic window between the transducer, skin and target lesion and absence of bowel loops across the planned ultrasound path)
Exclusion criteria
* general contraindication to MR imaging (including pacemaker, ferromagnetic devices or implants) * general contraindication to gadolinium-based contrast agents (intolerance and/or clinically proven chronic renal failure) * general contraindication to general/epidural anesthesia or deep sedation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety and efficacy of Magnetic Resonance-guided Focused Ultrasound (MRgFUS) for the primary treatment of painful bone metastases | 6 months | Patients will be monitored for major or minor adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To correlate the treatment response to extent of tumor necrosis as determined by follow-up imaging | 6 months | necrosis of the actual lesion will be analyzed according to area on non-perfused volume at the end of the procedure |
Countries
Italy
Outcome results
None listed